Posted by Michael Wonder on 29 Jan 2025
Santhera’s Duchenne muscular dystrophy drug Agamree accepted by SMC
16 January 2025 - The rare muscle wasting disorder affects approximately 2,500 males in the UK at any one time.
Santhera Pharmaceuticals’ Agamree (vamorolone) has been accepted by the Scottish Medicines Consortium to treat Duchenne muscular dystrophy in patients aged four years and older.
